Artificial antigen presenting cells for genetic engineering of immune cells
AssigneeH. Lee Moffitt Cancer Center and Research Institute, Inc.
InventorMarco Davila
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods of producing chimeric antigen receptor (CAR) T cells using substrates, such as artificial antigen presenting cells, containing on a surface a a heparin binding domain (HBD), anti-CD3 single chain antibodies, anti-CD28 single chain antibodies (scFv), and optionally anti-41BBL antibodies. Anti-CD3 and Anti-CD28 scFvs bind and activate expanding T cells ex vivo, while the Heparin Binding Domain binds the viral vector, thereby bringing the T cells into close proximity with virus for effective gene transfer. This is a less costly, renewable, modifiable, and efficacious alternative to coated beads and RetroNectin® for gene transfer.
Claims20
A method for producing chimeric antigen receptor (CAR) T cells comprising
- a) providing a fusion protein on an exposed surface of a substrate or on a lipid membrane, wherein the fusion protein comprises a heparin binding domain and one or more single chain variable fragments (scFv) comprising an antigen recognition domain that selectively binds a CD3 antigen and/or a CD28 antigen, and
- b) co-culturing a T cell, a viral vector encoding a chimeric antigen receptor, and an effective amount of the-fusion protein.
Dependencies are inferred from the claim text.